Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | EVP & Pres., Lilly Diabetes | February 10, 2023 | February 14, 2023 |
| WW INTERNATIONAL, INC.WW · Entity 6479 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date February 10, 2023 · Filed February 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,284 |
Reported balance
After 2023-02-10 transaction · row 1
1 source rowRow 1 · 2023-02-10 · Grant · Acquired 8,023 · Balance 39,284 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2024-02-01 | Direct | 3,490 |
Reported balance
After 2023-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-02-10 · Grant · Acquired 3,490 · Balance 3,490 F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 957 |
Reported balance
Holding disclosure · report date 2023-02-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 957 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
WW INTERNATIONAL, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,385 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 1,166 · Balance 2,385 F1: The shares listed represent shares of Common Stock subject to transfer restrictions. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares listed represent shares of Common Stock subject to transfer restrictions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:01 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 1,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004367 · ownership.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,385 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:01 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 1,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-328680 · ownership.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,219 F1 · date: This award was granted in connection with the Reporting Person's service as a member of the Issuer's Board of Directors during the third quarter of fiscal 2025. F2 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:49 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 3,490 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000055 · wf-form4_167641129919422.xml · derivative · entry 3 Mason Michael B · CIK 0001799419 · EVP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,490 Underlying: Common Stock · 3,490 shares Expires 2024-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:49 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 8,023 | $345.12 | $2,768,897.76 |
DisclosureSEC source: 0000059478-23-000055 · wf-form4_167641129919422.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · EVP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,284 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:51 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 6,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000035 · wf-form4_167546109073306.xml · derivative · entry 4 Mason Michael B · CIK 0001799419 · EVP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,690 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:51 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 2,935 | $344.15 | $1,010,080.25 |
DisclosureSEC source: 0000059478-23-000035 · wf-form4_167546109073306.xml · nonDerivative · entry 2 Mason Michael B · CIK 0001799419 · EVP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,261 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:51 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 6,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000035 · wf-form4_167546109073306.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · EVP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:19 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 6,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000044 · wf-form4_164462154515553.xml · derivative · entry 3 Mason Michael B · CIK 0001799419 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,690 Underlying: Common Stock · 6,690 shares Expires 2023-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:19 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 2,612 | $243.27 | $635,421.24 |
DisclosureSEC source: 0000059478-22-000044 · wf-form4_164462154515553.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,506 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:34 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6,350 | $205.77 | $1,306,639.50 |
DisclosureSEC source: 0000059478-21-000050 · wf-form4_161300725044581.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,894 Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 21:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 6,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000137 · wf-form4_159908062423990.xml · derivative · entry 4 Mason Michael B · CIK 0001799419 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,244 shares Expires 2020-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 21:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 2,735 | $148.39 | $405,846.65 |
DisclosureSEC source: 0000059478-20-000137 · wf-form4_159908062423990.xml · nonDerivative · entry 2 Mason Michael B · CIK 0001799419 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,544 Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 21:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 6,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-20-000137 · wf-form4_159908062423990.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 22:42 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 5,785 | $144.25 | $834,486.25 |
DisclosureSEC source: 0000059478-20-000032 · wf-form4_158163371681102.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,035 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.